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ABSTRACT 
 
According to WHO 2014 data, 9% of adults 18 years and older had 
diabetes. In 2012 diabetes was the direct cause of 1.5 million deaths. Until this 
date, diabetes mellitus has become a major healthcare burden in almost all 
countries in the world. According to the Third National Health and Morbidity 
Survey (2006) done by the Ministry of Health Malaysia, the prevalence of 
diabetes among Malaysian adults of over 30 years has almost increased by two 
folds. WHO states that non-adherence to medications is a major problem whereby 
poor adherence can lead to negative health outcomes such as worsened disease or 
even mortality. The aim of this study was to evaluate the effectiveness of 
pharmacist-managed DMTAC program in improving patients’ glycemic control, 
lipid profile, and medication adherence pre and at least 3 months post DMTAC 
program. This retrospective cross sectional study was carried out within 3 months 
at the out-patient pharmacy of Putrajaya Health Clinic Presint 9. Primary outcome 
measure was the glycemic control changes pre and post DMTAC service. Other 
relevant clinical parameters changes were the secondary outcome measures. There 
was a significant difference of mean HbA1c by -0.82%, which decreased from 
10.46% (S = 1.68) to 9.64% (SD = 2.34) (p<0.001). Meanwhile, the reduction of 
2.9 mmol/L (p<0.001) in mean FBG was also significant. This statistical 
significant difference of HbA1c indicates a positive impact of DMTAC program. 
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